Are we going to have a new class of medicines for ADHD?! SNDRIs (Serotonin-noradrenaline-dopamine reuptake inhibitors) are an existing class of medicines which have predominantly been used to treat Major Depressive Disorder. They are now being considered to potentially treat ADHD! This condition is complicated and many theories have been proposed. I personally believe there are multiple brain pathways and neurotransmitters that are affected in ADHD. I also think the affected brain regions differ according to the SUBTYPE of ADHD - inattentive, hyperactive or combined. If we started treating patients according to their ADHD subtype, we might see better results. Yes Methylphenidate has been shown to be very effective for ADHD.. but most of the studies supporting this were studies conducted in little boys who as we know, tend to show the hyperactive subtype of ADHD. However when we look at those with predominantly inattentive ADHD, will something like Methylphenidate be as effective? I personally don’t think so. This is where different medicines come into play. Triple reuptake inhibitors can simultaneously target all Dopamine, Serotonin AND Noradrenaline transmission. This could really help those with related mood symptoms not managed by current ADHD medicines, but also might help reduce the occurrence of side effects from stimulant medication! But it’s important to remember that ADHD medicines aren’t a magic pill that will cure everything. Combining them with lifestyle interventions is always the way forward in my opinion. SNDRIs do show a lot of promise, but every medicine has its flaws, so let’s see what happens with the ones that are already in clinical trials! #adhd #adhdtiktok #adultadhd #adhdmedication #adhdscience #adhdbrain #adhdadvice #adhdexplained #adhdresearch #serotonin #dopamine #noradrenaline #norepinephrine #adhdinwomen #adhdhelp #adhdawareness #adhdtips #pharmacist #medicine